Can HPV cause fatty liver? This question arises from understandable concern about two common health conditions, but it's important to clarify that human papillomavirus (HPV) and fatty liver disease affect entirely different organ systems through distinct mechanisms. HPV is a sexually transmitted virus primarily targeting epithelial tissues such as the cervix and throat, whilst fatty liver disease results from metabolic factors causing fat accumulation in liver cells. Current UK clinical guidance from NICE, the NHS, and UKHSA does not recognise any causal link between HPV infection and the development of hepatic steatosis. Understanding this distinction helps patients focus on the appropriate risk factors and management strategies for each condition separately.
Summary: No, HPV does not cause fatty liver disease—these are separate conditions affecting different organ systems with no recognised causal link in UK clinical guidance.
- HPV is a virus targeting epithelial tissues (cervix, throat, skin), not liver cells, with no documented effect on hepatic lipid metabolism.
- Fatty liver disease is primarily caused by metabolic factors including obesity, type 2 diabetes, insulin resistance, and excessive alcohol consumption.
- HPV exerts pathological effects through viral oncoproteins affecting tumour suppressor genes in epithelial cells, not hepatocytes.
- NICE guidance identifies lifestyle factors—not viral infections like HPV—as the primary drivers of non-alcoholic fatty liver disease in the UK.
- Any co-occurrence of HPV and fatty liver in the same individual reflects their respective prevalence rather than a causal relationship.
- Patients with concerns about both conditions should address them separately with appropriate screening and risk factor management.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Understanding HPV and Fatty Liver Disease
Human papillomavirus (HPV) and fatty liver disease are two distinct medical conditions that affect different organ systems and have separate underlying mechanisms. HPV is a group of more than 200 related viruses, with certain high-risk strains (particularly types 16 and 18) known to cause cervical, oropharyngeal, and other cancers. The virus is primarily transmitted through skin-to-skin contact, most commonly during sexual activity, and is one of the most prevalent sexually transmitted infections worldwide.
Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. There are two main categories: non-alcoholic fatty liver disease (NAFLD), which affects people who drink little to no alcohol, and alcohol-related liver disease (ARLD), the early stage of which is alcohol-related fatty liver, developing due to excessive alcohol consumption. NAFLD is increasingly common in the UK, affecting a substantial proportion of adults, often associated with metabolic conditions such as obesity, type 2 diabetes, and high cholesterol. Steatosis is defined as fat accumulation in 5% or more of liver cells (hepatocytes) on histology or validated imaging.
The liver performs over 500 vital functions, including filtering toxins, producing bile for digestion, storing energy, and manufacturing proteins essential for blood clotting. When fat accumulates beyond this threshold, simple steatosis can progress to more serious conditions such as non-alcoholic steatohepatitis (NASH), fibrosis, and potentially cirrhosis. Understanding the distinct nature of these conditions is essential when evaluating whether any connection exists between HPV infection and liver health, as they involve fundamentally different pathophysiological processes affecting separate organ systems.
Can HPV Cause Fatty Liver? Examining the Evidence
There is no recognised causal association between HPV infection and the development of fatty liver disease in UK clinical guidance. Current medical literature and guidance from organisations such as NICE, the NHS, and UKHSA do not identify HPV as a causative factor in hepatic steatosis. The mechanisms by which HPV affects human cells are primarily related to epithelial tissues—particularly those of the cervix, throat, and skin—rather than hepatocytes (liver cells).
HPV exerts its pathological effects through viral oncoproteins, particularly E6 and E7, which interfere with tumour suppressor genes in infected epithelial cells. This mechanism is well-characterised in the development of cervical and oropharyngeal cancers but has no known direct impact on hepatic lipid metabolism or the pathways leading to fat accumulation in the liver. The virus does not replicate in liver tissue, and there is no documented tropism (tissue preference) of HPV for hepatocytes.
Whilst some viral infections—such as hepatitis B and C viruses—are well-established causes of liver disease including steatosis, HPV belongs to a different viral family (Papillomaviridae) with entirely different cellular targets and disease mechanisms. It is important to note that having HPV does not increase your risk of developing fatty liver disease through any known biological pathway. If you have concerns about both HPV and liver health, these should be addressed as separate medical issues, each with its own risk factors, screening protocols, and management strategies. Any coincidental occurrence of both conditions in the same individual would reflect their respective prevalence in the population rather than a causal relationship.
Common Causes of Fatty Liver Disease in the UK
Fatty liver disease in the UK is predominantly driven by metabolic and lifestyle factors rather than infectious agents. The primary risk factors for NAFLD include:
-
Obesity and overweight: Excess body weight, particularly central adiposity (fat around the abdomen), is the strongest predictor of NAFLD
-
Type 2 diabetes and insulin resistance: Impaired glucose metabolism promotes hepatic fat accumulation
-
Dyslipidaemia: Elevated triglycerides and low HDL cholesterol contribute to liver fat deposition
-
Metabolic syndrome: A cluster of conditions including hypertension, abnormal cholesterol, elevated blood glucose, and abdominal obesity
-
Sedentary lifestyle: Physical inactivity reduces the liver's ability to metabolise fats effectively
For alcohol-related liver disease (ARLD), excessive alcohol consumption is the direct cause. The UK Chief Medical Officers advise that to keep health risks from alcohol low, it is safest not to drink more than 14 units of alcohol per week on a regular basis. Once ARLD is present, abstinence from alcohol is recommended, and referral for alcohol support services may be appropriate. The liver prioritises metabolising alcohol over other nutrients, leading to fat accumulation and, with continued drinking, progressive liver damage.
Other contributing factors include:
-
Certain medications: Corticosteroids, tamoxifen, methotrexate, and some antiretroviral drugs may contribute to hepatic steatosis. Do not stop prescribed medicines without discussing this with your doctor first.
-
Rapid weight loss: Paradoxically, losing weight too quickly can temporarily worsen liver fat
-
Nutritional factors: Diets high in refined carbohydrates and fructose
-
Genetic predisposition: Variations in genes such as PNPLA3 increase susceptibility
According to NICE guidance (NG49), the management of NAFLD focuses on addressing these modifiable risk factors through lifestyle interventions, including gradual weight loss (7–10% of body weight), increased physical activity (at least 150 minutes of moderate-intensity aerobic activity weekly, plus muscle-strengthening activities on at least two days per week, in line with UK Chief Medical Officers' guidelines), and dietary modifications emphasising whole foods whilst limiting processed foods, sugary beverages, and saturated fats. Understanding these established causes helps patients and healthcare professionals focus preventive and therapeutic efforts appropriately.
If you experience side effects from any medication, report these via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.
HPV-Related Health Conditions and Liver Function
Whilst HPV does not directly cause liver disease, it is important to understand the full spectrum of HPV-related health conditions. HPV infections primarily cause:
-
Genital warts: Caused by low-risk HPV types (6 and 11)
-
Cervical cancer: Predominantly linked to high-risk types 16 and 18
-
Other anogenital cancers: Including vulval, vaginal, penile, and anal cancers
-
Oropharyngeal cancers: Increasingly recognised as HPV-related, particularly in younger adults
-
Skin warts: Common cutaneous manifestations of various HPV types
The liver plays a crucial role in metabolising medications used to treat HPV-related conditions. For instance, patients undergoing chemotherapy or immunotherapy (such as immune checkpoint inhibitors) for HPV-associated cancers may experience drug-induced liver injury, though this relates to the treatment rather than the virus itself. Regular liver function tests (LFTs) are routinely monitored during many systemic cancer therapies to detect any hepatotoxicity early. If you develop symptoms such as jaundice, dark urine, or persistent nausea during cancer treatment, contact your oncology team promptly.
There is no robust evidence that HPV infection influences hepatic lipid metabolism or contributes to fatty liver development. The immune response to HPV is localised to infected tissues and does not produce the systemic metabolic disturbances characteristic of conditions that cause fatty liver.
Patients with HPV-related conditions who also have fatty liver disease should understand these are coincidental rather than causally related. However, maintaining overall health—including liver health—is important for anyone, particularly those undergoing treatment for HPV-related cancers, as optimal liver function supports the body's ability to process medications and maintain immune function. If you have concerns about how HPV-related treatments might affect your liver, discuss this with your oncologist or specialist, who can arrange appropriate monitoring.
When to Seek Medical Advice About Liver Health
Fatty liver disease often develops silently without symptoms in its early stages, making awareness of risk factors and appropriate screening essential. You should consult your GP if you have multiple risk factors for fatty liver disease, including obesity, type 2 diabetes, high cholesterol, or metabolic syndrome, even in the absence of symptoms.
Seek medical attention if you experience:
-
Persistent fatigue or weakness that affects daily activities
-
Discomfort or pain in the upper right abdomen (where the liver is located)
-
Unexplained weight loss without dietary changes
-
Jaundice: Yellowing of the skin or whites of the eyes
-
Dark urine or pale stools: Suggesting impaired bile flow
-
Easy bruising or bleeding: Indicating reduced liver synthetic function
-
Swelling in the legs or abdomen: Signs of advanced liver disease
Seek urgent same-day assessment or emergency care if you experience confusion or drowsiness, vomiting blood or passing black tarry stools, rapidly increasing abdominal swelling, or fever with jaundice or right upper abdominal pain.
Your GP can arrange blood tests to assess liver function, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), bilirubin, and albumin. Tests of synthetic function such as the international normalised ratio (INR) or prothrombin time may also be checked. Elevated liver enzymes may prompt further investigation with ultrasound scanning to detect steatosis or specialised tests such as transient elastography (FibroScan) to assess liver fibrosis; where available, the controlled attenuation parameter (CAP) can quantify steatosis.
NICE recommends (NG49) that adults with NAFLD should be assessed for advanced fibrosis using validated non-invasive scoring systems. In primary care, the FIB-4 score or NAFLD Fibrosis Score (with age-adjusted cut-offs) is used first. If results are indeterminate or suggest increased risk, confirmatory testing with the Enhanced Liver Fibrosis (ELF) blood test or transient elastography is arranged. Patients with suspected advanced fibrosis are referred to hepatology services for specialist assessment and management.
If you have concerns about both HPV and liver health, discuss these separately with your healthcare provider. Cervical screening is offered to women and people with a cervix in the UK; in England, this is every three years for those aged 25–49 and every five years for those aged 50–64 (intervals vary slightly across UK nations). Liver health assessment depends on individual risk factors.
Do not delay seeking medical advice if you experience symptoms suggesting advanced liver disease, as early intervention can prevent progression to cirrhosis and liver failure. Maintaining regular contact with your GP and attending recommended screening programmes provides the best opportunity for early detection and management of both HPV-related conditions and liver disease.
Scientific References
- Non-alcoholic fatty liver disease (NAFLD): assessment and management.
- Non-alcoholic fatty liver disease (NAFLD).
- Managing specific infectious diseases: A to Z.
- Human papillomavirus (HPV).
- The NHS Cervical Screening Programme.
- Low Risk Drinking Guidelines.
- Physical activity guidelines.
- Assessing liver function and interpreting liver blood tests.
- Prostap 3 DCS 11.25 mg Summary of Product Characteristics.
- Tamoxifen 20mg Film-Coated Tablets Summary of Product Characteristics.
- Methotrexate 2mg/ml Oral Solution Summary of Product Characteristics.
- The Yellow Card scheme: guidance for healthcare professionals.
Frequently Asked Questions
Does having HPV increase my risk of developing fatty liver?
No, having HPV does not increase your risk of developing fatty liver disease through any known biological pathway. HPV affects epithelial tissues such as the cervix and throat, whilst fatty liver results from metabolic factors like obesity, diabetes, and excessive alcohol consumption—these are entirely separate conditions with no recognised causal link in UK clinical guidance.
What viruses actually cause liver disease?
Hepatitis B and hepatitis C viruses are well-established causes of liver disease, including steatosis, inflammation, and cirrhosis. HPV belongs to a different viral family (Papillomaviridae) with entirely different cellular targets and does not replicate in liver tissue or affect hepatic lipid metabolism.
If I have HPV and fatty liver, are they connected?
No, if you have both HPV and fatty liver disease, these conditions are coincidental rather than causally related. Each condition has its own distinct risk factors, screening protocols, and management strategies that should be addressed separately with your healthcare provider.
What are the main causes of fatty liver in the UK?
The primary causes of fatty liver disease in the UK are obesity, type 2 diabetes, insulin resistance, high cholesterol, metabolic syndrome, and excessive alcohol consumption. NICE guidance emphasises lifestyle interventions including gradual weight loss, increased physical activity, and dietary modifications as the cornerstone of management.
How do I know if I need testing for fatty liver?
You should consult your GP if you have multiple risk factors such as obesity, type 2 diabetes, high cholesterol, or metabolic syndrome, even without symptoms. Your GP can arrange blood tests to assess liver function and, if needed, imaging such as ultrasound or FibroScan to detect steatosis and assess for fibrosis.
Can treatments for HPV-related cancers affect my liver?
Yes, chemotherapy and immunotherapy used to treat HPV-associated cancers can potentially cause drug-induced liver injury, though this relates to the treatment rather than the virus itself. Regular liver function tests are routinely monitored during systemic cancer therapies, and you should report symptoms such as jaundice, dark urine, or persistent nausea to your oncology team promptly.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
